CALC.US CalciMedica, Inc. Common Stock

Healthcare Biotechnology USA Stocks
1.21 USD
Close of Nov 13, 2026
1.00 36.00
Market cap
USD 8.34M
P/E
-
P/B
2.07x
ROE
-137.2%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is CALC.US undervalued?

Graham number

The Graham number of CalciMedica, Inc. Common Stock cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

CalciMedica, Inc. Common Stock fundamental analysis

No fundamental analysis for CalciMedica, Inc. Common Stock yet.

CalciMedica, Inc. Common Stock stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About CalciMedica, Inc. Common Stock

CalciMedica, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. Its lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated calcium (CRAC) channel inhibitors for the treatment of acute pancreatitis, asparaginase-induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia. The company…

Full company profile